Search

Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction

New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Albertans living with chronic conditions benefit from home monitoring

Helping patients by addressing health system gaps

Getting INSPIRED about improving care for people living with Chronic Obstructive Pulmonary Disease (COPD)

Digital technology helps patients with complex needs

Virtual care pharmacy services offered in Alberta long-term care facilities

Successful virtual care model grows thanks to collaboration

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase

Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease

Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients

Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

Using AI to power patient-centric guideline optimization

The Type 2 Spark Innovation Challenge

Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases

PIPEDA Terms of Use Consent - Contact us form - english

Tackling care gaps in respiratory diseases in Alberta

Alberta’s Dr. Calvin Booker named bovine veterinarian of the year by the Western Canadian Association of Bovine Practitioners

Accessible Customer Service Policy

Legal Notices

Boehringer Ingelheim shares updated 2030 environmental sustainability commitments

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction

New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Albertans living with chronic conditions benefit from home monitoring

Helping patients by addressing health system gaps

Helping patients by addressing health system gaps

Helping patients by addressing health system gaps

Getting INSPIRED about improving care for people living with Chronic Obstructive Pulmonary Disease (COPD)

Digital technology helps patients with complex needs

Virtual care pharmacy services offered in Alberta long-term care facilities

Successful virtual care model grows thanks to collaboration

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase

Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease

Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients

Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Using AI to power patient-centric guideline optimization

The Type 2 Spark Innovation Challenge

Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases

PIPEDA Terms of Use Consent - Contact us form - english

Tackling care gaps in respiratory diseases in Alberta

Alberta’s Dr. Calvin Booker named bovine veterinarian of the year by the Western Canadian Association of Bovine Practitioners

Accessible Customer Service Policy

Legal Notices

Boehringer Ingelheim shares updated 2030 environmental sustainability commitments